Clinical Overview: Fecal Microbiota Transplantation vs Live Biotherapeutic Products for Management of Recurrent C Difficile Infection

Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.

Related Keywords

United States ,America ,Glenns Tillotson ,Anne Gonzales Luna ,Torres Soto ,American College Of Gastroenterology ,Infectious Diseases Society Of America ,Ferring Pharmaceuticals Inc ,Forum Infect Dis ,Department Of Pharmacy Practice ,Society For Healthcare Epidemiology Of America ,Translational Research ,University Of Houston College Pharmacy ,Fecal Microbiota Transplantation National Registry ,Infectious Diseases Society ,American College ,Pharmacy Practice ,Houston College ,Practice Guideline ,Healthcare Epidemiology ,Update Guidelines ,Clin Infect ,Practice Guidelines ,Microbiota Transplantation National Registry ,Bacteremia Transmitted ,Fecal Microbiota ,Safety Alert ,Serious Adverse Events Likely Due ,Pathogenic Organisms ,Clinical Trials ,Control Information ,Recurrent Clostridioides ,Purified Investigational Microbiome Therapeutic ,Reduces Risk ,Coronavirus Transmission From Donor ,Open Forum Infect ,